52 results about "Compounding drugs" patented technology

The invention relates to the technical field of anti-enterovirus medicines, in particular to application of Enractevir in preparation of an anti-enterovirus medicine. According to the invention, efficient screening of candidate drugs is realized through a multi-channel virus reporting system based on a TAT trans-activation effect, and a small molecule compound drug Enractevir with a specific antiviral effect on enterovirus group A 71 and enterovirus group D 68 is obtained. Enractevir improves the interferon secretion level of host cells by inhibiting the activity of enterovirus 2A / 3C protease, thereby inhibiting virus replication and proliferation. Enractevir plays a role through double-target 2A / 3C protease, and the risk of virus drug resistance can be reduced. According to the technical scheme, the technical problem that in the prior art, specific drugs for the two kinds of enteroviruses are lacked can be solved, a standardized treatment scheme is provided for prevention and control of enterovirus related diseases in the global range, and the medicine has remarkable public health significance and wide application and popularization value.

The invention relates to the field of medical rubber, in particular to a high-performance syringe rubber protective cap and a preparation method of the high-performance syringe rubber protective cap. The rubber material is prepared from the following components in parts by weight: 100 to 150 parts of modified polyisoprene, 5 to 10 parts of alkaline white carbon black, 30 to 50 parts of calcined kaolin, 1 to 2 parts of peroxide, 0.2 to 0.5 part of vulcanization accelerator, 1 to 3 parts of stearic acid, 5 to 15 parts of ultrahigh molecular weight polyethylene powder, 1 to 2 parts of carbon black and 5 to 10 parts of dimethyl silicone oil. The syringe rubber protective cap prepared by the invention has excellent puncture resistance, air tightness and environmental protection property, and does not easily generate adverse reaction with compound medicines.

An anti-inflammatory drug compound, and a preparation method therefor and the use thereof. The structural formula of the compound is A-Y—B, wherein A is a group after dehydrogenation of an amine compound having JAK inhibitory activity, Y is a direct connection or —(CH2)-O— or, and B is a group formed by means of dehydroxylation of a carboxy-containing carboxylic acid compound B1, or a group formed by means of dehydrogenation of a hydroxy-containing compound B2. The compound has the special effects of having a strong transdermal property, controlled drug release, high efficacy, etc.

The invention belongs to the technical field of medicine preparation, and particularly relates to an anti-HIV infection compound medicine microsphere composition, a medicine preparation and application. The invention firstly provides an anti-HIV (Human Immunodeficiency Virus) infection compound drug microsphere composition, which is composed of Cabotegravir, rilpivirine and at least one polylactic acid-glycolic acid copolymer, and comprises a first compound microsphere composition or a second compound microsphere composition, wherein one of the microsphere compositions is a co-coated microsphere formed by co-coating Cabotegravir and rilpivirine in the same microsphere; and the other microsphere composition is a mixture consisting of a microsphere for wrapping Cabotegravir and a microsphere for wrapping rilpivirine. The invention aims to provide a flexible preparation platform so as to optimize the long-acting treatment effect of the two anti-HIV drugs. For a composition form that one microsphere wraps two medicines, synchronous release and long-acting release of the two medicines are realized as much as possible; for another physically mixed composition form, independent regulation of release kinetics of a single drug is achieved as much as possible, so that the same administration cycle is achieved. The pharmaceutical preparation disclosed by the invention can be used for prevention before HIV exposure and long-term maintenance treatment of infected persons, and can be used for remarkably improving medication compliance and reducing the risk caused by virus drug resistance.

The invention relates to a combined application of a benzimidazole compound and a BCR-ABL1TKI inhibitor in preparation of a medicine for treating leukemia related diseases, and provides a combined application of the benzimidazole compound and the BCR-ABL1TKI inhibitor in preparation of a medicine for preventing or treating leukemia related diseases.

This invention provides a compound drug for treating melioidosis, its preparation method, and its application. The drug comprises active components of traditional Chinese medicine, a bioactive preparation, and a pharmaceutically acceptable carrier. The active components of traditional Chinese medicine are primarily extracts of Scutellaria baicalensis, Coptis chinensis, Fagopyrum dibotrys, and Polygonum cuspidatum. The bioactive preparation includes polymyxin B, homoserine lactonease, and recombinant human β-defensin 3. The components work synergistically to construct a comprehensive intervention system covering all pathological stages, including biofilm disruption, sterilization, anti-endotoxin activity, intracellular bacterial clearance, immune regulation, and tissue repair. This system can effectively disrupt bacterial biofilms, kill multidrug-resistant strains, neutralize endotoxins, and eliminate latent intracellular bacteria, addressing the core pain points of existing melioidosis treatments, such as strong drug resistance, significant toxic side effects, and high recurrence rates. The preparation process of this invention is carried out under low-temperature and sterile conditions throughout, which fully preserves the stability of the active ingredients, making it suitable for industrial production. The drug can be prepared in various dosage forms, covering all clinical subtypes of melioidosis, and possesses clinical application value and promising prospects for widespread application.

The invention discloses a network dynamics method and system of complex numbers and trigonometric functions for representing medicine vibration and rhythm effects and a storable medium thereof, and belongs to the field of biological medicine effect analysis. The method comprises the following steps: S1, establishing a network dynamics mathematical model of a complex number and a trigonometric function according to vibration and rhythmicity characteristics of medical action; s2, measuring the intensity of the observation index at different time points, and obtaining a time sequence effect curve of the observation index; s3, performing curve fitting on the time sequence effect curve obtained in the S2 based on the mathematical model established in the S1 to obtain a plurality of action parameters, and constructing a quantity-time curve or an effect-time curve based on the plurality of action parameters; and S4, performing statistical moment analysis on the quantity-time curve or the effect-time curve constructed in the S3, and analyzing action quantity-time-effect parameters to obtain the vibrativity, the rhythmicity and the network action rule of the medical action. The invention has breakthrough significance for developing new compound medicines and diagnosis and treatment equipment, and has huge potential economic benefits.

The invention discloses a nano-sized iron-oxygen cluster compound drug molecule, a preparation method and application of the nano-sized iron-oxygen cluster compound drug molecule in preparation of sepsis treatment drugs, and belongs to application of the nano-sized iron-oxygen cluster compound drug molecule in the aspect of disease treatment. The method comprises the following steps: sequentially adding ferric nitrate, L-(+)-tartaric acid and gadolinium nitrate into a magnesium acetate-acetic acid buffer solution, uniformly stirring, and then adding carbonate; and cooling to room temperature after water bath, filtering, carrying out evaporation culture on the obtained filtrate at 25 DEG C, and carrying out vacuum drying to obtain the nano-sized iron-oxygen cluster compound drug molecule. The nano-sized iron-oxygen cluster compound drug molecule prepared by the invention reduces the burden of blood and peritoneal fluid bacteria of a cecum ligation puncture mouse by activating B cells in the mouse body and increasing the natural antibody level, improves the liver injury and lung injury of the mouse, reduces the proportion of inflammatory factors and inflammatory cells in the mouse body, and improves the curative effect of the mouse. Therefore, the death rate of sepsis model mice is effectively reduced, the action effect is remarkable, and the traditional Chinese medicine composition has unique advantages in the application aspect of treating sepsis.

The invention relates to the field of traditional Chinese medicine compositions, and particularly discloses a traditional Chinese medicine composition for detoxifying, dredging collaterals, eliminating paste and stabilizing sugar and a preparation method thereof. The traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 7 to 15g of rhizoma coptidis, 6 to 10g of wine-treated rhubarb, 15 to 30g of radix astragali seu hedysari, 12 to 15g of radix salviae miltiorrhizae, 12 to 20g of radix paeoniae rubra, 6 to 10g of radix bupleuri, 6 to 10 parts of herba artemisiae scopariae, 7 to 15 parts of fructus crataegi and 7 to 15 parts of pericarpium citri reticulatae. The detoxifying, collateral dredging, ointment eliminating and sugar stabilizing traditional Chinese medicine composition can achieve the effects of reducing blood sugar fluctuation and lipid deposition on the basis of achieving the effects of reducing blood sugar and improving the insulin resistance level, can effectively reduce the dosage of compound medicine for a patient so as to improve the compliance of the patient, is safe and effective, delays the occurrence of diabetes complicated diseases and complications, and has a wide application prospect. And the living quality of the patient is improved.

The present invention relates to a compound drug for preventing and treating porcine reproductive and respiratory syndrome (PRRS), belonging to the field of veterinary drugs. The present invention makes an oral pharmaceutical preparation by mixing an animal-specific macrolide drug, sodium houttuyfonate, mannan oligosaccharide peptide and pharmaceutical excipients in a certain proportion. The drug of the present invention can effectively treat acute-phase PRRS, rapidly relieve the clinical symptoms of diseased pigs and improve the survival rate.

The invention discloses an ultrasonic helmet-medicine composite administration instrument. The device comprises a power supply module, a single-chip microcomputer micro-control unit and an ultrasonic drive circuit power supply, a 7.4 V battery is adopted to be connected with a single-chip microcomputer, and pulse width modulation waves are sent by the micro-control unit module, reach a transducer through a booster circuit and then are fed back to the micro-control module through a sampling circuit. A receptor of the temperature sensor is arranged in the ultrasonic transducer, the main control is carried out on the single chip microcomputer, and when the temperature exceeds 50 DEG C, the power is automatically cut off to protect the skin. The working frequency of the transducer is 3MHz, the working power is 3-6W, the total diameter is 20mm, and the height is 20mm. In order to enable ultrasonic waves to have a better penetrating effect, the surface of the transducer is designed to be a concave surface, and a lead zirconate titanate material is used. The helmet is printed by using thermoplastic polyurethane rubber through a fused deposition 3D printing technology, and the helmet is used for fixing the transducer to the head. The device is small in size, can be worn at any time, is suitable for non-invasive external use, can improve the drug treatment effect, and is good in safety.

The invention discloses a compound polymyxin inhalation preparation which is composed of polymyxin polypeptides, aminoglycoside antibiotics and pharmaceutically acceptable auxiliary materials, the molar ratio of the polymyxin polypeptides to the aminoglycoside antibiotics in the inhalation preparation is (1: 20)-(1: 80), and the molar ratio of the polymyxin polypeptides to the aminoglycoside antibiotics in the compound proportion is 1t compared with the molar ratio of a single component or the molar ratio of the aminoglycoside antibiotics in the single component; a compound proportion condition of 1: 20 can significantly reduce lung toxicity and also can achieve a drug effect of significantly eliminating lung infection multi-drug-resistant bacteria, the compound drug is delivered by adopting an inhalation liquid preparation form, the total drug delivery efficiency of aerosol inhalation is greatly improved, the median particle size of the drug is smaller, the proportion of particles smaller than 5 [mu] m exceeds 55%, and the drug delivery efficiency of aerosol inhalation is greatly improved. The medicine is more easily inhaled into the lung to achieve an anti-infection treatment effect.

The invention discloses a Zhuang medicine compound medicine for treating insomnia and a preparation method of the Zhuang medicine compound medicine, and the Zhuang medicine compound medicine comprises the following raw materials in parts by weight: 17-24 parts of wintercreeper, 12-16 parts of gastrodia elata, 13-18 parts of spina date seed, 11-17 parts of platycladi seed and 8-12 parts of poria with hostwood. The preparation method of the Zhuang medicine compound medicine comprises the following steps: a, weighing the euonymus fortunei, the gastrodia elata, the spina date seeds, the platycladi seeds and the poria with hostwood according to the weight ratio; and b, putting the raw materials weighed in the step a into water, and decocting the raw materials to prepare liquid medicine, so as to prepare the Zhuang medicine compound medicine for treating insomnia. The Zhuang medicine compound medicine provided by the invention has the characteristics of being economical and practical, convenient to use, remarkable in effect, capable of consolidating basis, smoothing the dragon road, nourishing the fire road, calming the heart and soothing the nerves, small in toxic and side effects and the like, and shows many advantages.

The present invention belongs to the field of medical technology, and in particular to the application of BMS-265246 in the preparation of anti-herpes virus drugs and pharmaceutical compositions. The present invention provides a novel small molecule compound drug for herpes simplex virus, and the effective drug concentration of BMS-265246 for anti-herpes virus is low, and the safety is good, the selection index at the cell level is high, and the therapeutic index at the animal level is high. It can improve the survival rate of mice infected with a lethal dose of herpes virus, reduce the weight loss of mice, reduce lung tissue pathological damage, and have a good therapeutic effect on diseases caused by herpes virus infection, and has a broad-spectrum and efficient anti-herpes virus effect; in addition, BMS-265246 targets host cell proteins, and basically does not produce virus resistance problems, and provides new ideas and treatment schemes for inhibiting herpes virus replication and clinically preventing and / or treating diseases caused by herpes virus infection.

To provide a system for verifying pharmaceutical compounding.SOLUTION: A system for verifying pharmaceutical compounding includes: a computing device provided with a user interface providing an instruction as to whether or not compounded drug is administered to a patient, and at least one processor operably combined with the user interface; and a bar code scanner operably combined to at least the one processor. The at least one processor receives bar code data from the bar code scanner. The bar code data is configured to: include data about the compound drug; compare the bar code data with the patient's data and / or prescription data; and verify that the compound drug can be administered to the patient.SELECTED DRAWING: Figure 2

The present invention belongs to the field of biomedical technology and discloses a method for screening drugs targeting histone deacetylase SIRT6 regulators. Based on testing the affinity between SIRT6 protein and small molecules with SYPRO Orange Protein Gel Staining Solution, this method constructs a drug screening model to screen for SIRT6 regulator-targeting drugs. The drug screening model constructed by the present invention is applicable to screening monomeric compound drugs with strong affinity effects (including agonists and inhibitors) on histone deacetylase SIRT6, and the action sites of the screened compounds are clear; the screening of monomeric compound drugs using this drug screening model has the advantages of high throughput, small protein consumption, low concentration, low cost, strong specificity, and convenient operation, providing a new and effective option for the screening of histone deacetylase SIRT6 regulators in this field, having good application prospects, and successfully screening out monomeric compound drugs with strong targeting effects on SIRT6 protein.

The invention discloses a radix scutellariae extract for resisting Helicobacter pylori, a preparation method thereof and a composite drug. The invention first obtains a radix scutellariae water extract by a water extraction method, and then extracts the radix scutellariae extract by using ethyl acetate as a solvent. In vitro experiments show that the method enriches the main active substances of radix scutellariae for resisting Helicobacter pylori, has a significant antibacterial effect on the standard strain SS1 of Helicobacter pylori, and has a minimum inhibitory concentration (MIC) of 32 μg / ml, which significantly inhibits the biofilm formation of the standard strain SS1 of Helicobacter pylori. In addition, it is also found that the radix scutellariae extract of the invention is used in combination with antibiotics commonly used in clinical treatment of HP infection, and has a synergistic effect with metronidazole and levofloxacin, and an additive effect with clarithromycin and amoxicillin, which has the effect of reducing the amount of antibiotics used in clinical application, and has potential application value for improving the current status of antibiotic resistance. Compared with the water extract, the MIC of the radix scutellariae extract extracted by the invention against Helicobacter pylori is greatly reduced, and the in vitro antibacterial activity is significantly enhanced.

The invention belongs to the field of compound medicines, and particularly relates to an eEF2K inhibitor which is a compound with a structure # imgabs0 # in a formula 1 and a pharmaceutically acceptable crystal or salt thereof. In the formula 1, R1 is O or-NR3, and R2 is a carbon chain of C1 to C20 or an oxa carbon chain; and R3 is H or a carbon chain of C1 to C10. The invention also comprises a preparation method of the eEF2K inhibitor and application of the eEF2K inhibitor in preparation of antitumor drugs. The invention provides a small molecule compound with a structure of a brand new formula 1, and the compound can accidentally have excellent eEF2K inhibitory activity, so that excellent pharmacological activities such as anti-tumor activity can be obtained based on the compound.

The invention relates to the technical field of polypeptide compound drugs, in particular to a polypeptide compound and a pharmaceutical composition and application thereof. The invention discloses a polypeptide compound. The polypeptide compound has a structural formula (XX), the polypeptide compound disclosed by the invention shows good osteogenic activity in vitro and has relatively good pharmacokinetic characteristics, so that the polypeptide compound has a potential application value in osteoporosis treatment.

The present application provides a 3-(3,5-dichloro-4-hydroxybenzoyl)-1,1-dioxo-2,3-dihydro-1,3-benzothiazole compound bulk drug, wherein the particle size D90 of the compound bulk drug is 70-5 μm. The present application also provides a composition comprising the bulk drug and an excipient. The bulk drug or the composition is used in the preparation of a drug for promoting the excretion of uric acid. The bulk drug of the present application can make the pharmaceutical composition comprising the same have better content uniformity and faster dissolution rate.

This invention provides an immunomodulatory and anti-fatigue agent and its preparation method, belonging to the field of traditional Chinese medicine technology. The invention provides an immunomodulatory and anti-fatigue agent composed of black goji berry polysaccharide and yellow-green mushroom polysaccharide, possessing immunomodulatory and anti-fatigue effects. The prepared compound drug shows regulatory effects on metabolites and oxidative enzymes in fatigue model mice, as well as immunomodulatory effects on LPS-induced RAW 264.7 macrophages. The black goji berry polysaccharide LRWP extracted by this method has a sugar content of 54.7%, a uronic acid content of 0.9%, and a protein content of 1.3%; the yellow-green mushroom crude polysaccharide HMGWP has a sugar content of 25.7%, a uronic acid content of 0.4%, and a protein content of 4.8%.

The invention discloses a preparation method of a florfenicol composite drug, and belongs to the technical field of pharmaceutical preparations, the preparation method comprises the following steps: adding florfenicol into a chitosan solution, and attaching the florfenicol to chitosan to form a precursor compound; then an arthrospira sulfated polysaccharide extract is added into the precursor compound, due to the binding force between the arthrospira sulfated polysaccharide extract and chitosan, composite particles coated with florfenicol are formed, and the arthrospira sulfated polysaccharide extract is located on the periphery of the composite particles, so that the composite particles are hydrophilic and carry negative charges; the composite particles coated with the florfenicol are the florfenicol composite medicine. According to the scheme, the use variety of drugs is reduced, the compound drug integrates multiple treatment functions into one drug, the variety of drugs needing to be taken by a patient at the same time is reduced, and the treatment scheme is simplified. According to the scheme, the florfenicol hydrogel has the characteristics of biocompatibility and degradability, the water solubility of florfenicol is improved, the reaction process is very simple, and the florfenicol hydrogel is suitable for industrial production.

The application belongs to the technical field of medicine, and discloses the use of a composition targeting the intestinal flora-UCP1 axis in preventing and / or treating metabolic syndrome and complications thereof. Specifically, the application relates to the use of tea extract, panax notoginseng extract and dendrobium extract in combination as active ingredients in the treatment of metabolic syndrome and complications thereof, and the use of any two or more of tea extract, panax notoginseng extract and dendrobium extract as active ingredients in combination with other active ingredients and excipients in the preparation of a compound drug preparation for clinical use in a daily dosage of 0.001-2000 mg / kg body weight. The application has a synergistic effect, is used for treating metabolic syndrome and complications thereof, reduces the dosage of a single agent, improves the prevention and treatment effect, reduces side effects, lowers the cost, and meets the basic requirements of health economics.

The invention discloses a compound medicine solution and a preparation method thereof, and belongs to the technical field of pharmacy, the compound medicine solution comprises the following active ingredients: sodium picosulfate, anhydrous citric acid and magnesium oxide; inactive components: a chelating agent, a bacteriostatic agent, an antioxidant, a flavoring agent and a sweetener; the invention also comprises a buffer solution system for keeping the product stable. A series of methods for maintaining the stability of an oral solution system meeting conditions are provided by taking the buffer capacity as an index, the process is finally simplified, and the prepared compound sodium picosulfate oral solution is stable.

The invention discloses a preparation method of lung-targeted hemoglobin nanoparticles, a drug-loaded hemoglobin nanoparticle solution and application, and relates to the technical field of nano medicine. The hemoglobin with a lung targeting function is used as a drug carrier, and the hemoglobin is improved to have a drug loading function and can be used for loading drug active substances to act on the lung, so that the drug active substances can realize accurate lung targeting therapy, the bioavailability of the drug is improved, and the dosage is reduced. The drug-loaded hemoglobin nanoparticle solution provided by the invention belongs to an antibiotic-hemoglobin nanoparticle compound drug delivery system, and has the advantages of increasing the distribution of antibiotics in targeted lung tissues and improving the availability. The preparation method of the lung-targeted hemoglobin nanoparticles provided by the invention is simple and good in repeatability, and industrial production is easy to realize.

The application discloses a compound polymyxin inhalation preparation, which is composed of a polymyxin polypeptide, an aminoglycoside antibiotic and a pharmaceutically acceptable auxiliary material. The molar ratio of the polymyxin polypeptide to the aminoglycoside antibiotic in the inhalation preparation is 1:20-1:80. Compared with single preparation or a compound preparation with a molar ratio of less than 1:20, the compound preparation with the molar ratio can significantly reduce lung toxicity and achieve a significant effect of clearing multiple drug-resistant bacteria in lung infection. The compound drug is delivered by using an inhalation liquid preparation dosage form, so that the total drug delivery efficiency of atomization inhalation is greatly improved, the median particle size of the drug is smaller, and the proportion of particles with a size of less than 5 microns is more than 55%, so that the drug is more easily inhaled into the lung to achieve an anti-infection treatment effect.

The invention provides a 3-(3, 5-dichloro-4-hydroxybenzoyl)-1, 1-dioxo-2, 3-dihydro-1, 3-benzothiazole compound bulk drug, and the particle size D90 of the compound bulk drug is 70 to 5 [mu] m. The invention also provides a composition which comprises the raw material medicine and an excipient. The raw material medicine or the composition is applied to preparation of medicines for promoting excretion of uric acid. According to the raw material medicine disclosed by the invention, the medicine composition containing the raw material medicine has relatively excellent content uniformity and relatively high dissolution rate.

This invention belongs to the field of compound drug technology. It relates to an N-aryl ketone acid cyanine compound with the structure of general formula (I), obtained by a dehydration condensation reaction of a ketone acid compound of formula (II) and a diphenylamine derivative of formula (III) upon heating. The product structure has a donor-acceptor-donor conjugated structure. These compounds are structurally stable, possess good light-harvesting ability, and under laser irradiation, simultaneously exhibit reactive oxygen species generation and photothermal conversion capabilities, combining photodynamic and photothermal properties. They are non-toxic to cells, have good biocompatibility, and can be used as photosensitizers in the combined photothermal and photodynamic therapy of tumors.

The invention belongs to the technical field of biological medicines, and particularly relates to a composite medicinal preparation for treating diabetic retinopathy and a preparation method thereof. The traditional Chinese medicine composition comprises traditional Chinese medicine raw materials and auxiliary materials, the traditional Chinese medicine raw materials comprise the following components: an astragalus extract, a salvia miltiorrhiza water-soluble extract, a salvia miltiorrhiza fat-soluble extract, panax notoginseng saponins, a scutellaria baicalensis extract, a ginkgo leaf extract, a lycium barbarum polysaccharide extract and quercetin; the auxiliary materials comprise the following components: soybean lecithin, tween-80, PEG-40 hydrogenated castor oil, medium chain triglyceride oil, glycerol, vitamin E, Arabic gum, maltodextrin, microcrystalline cellulose, PVP K30, croscarmellose sodium and silicon dioxide. On the basis of conventional ophthalmic treatment, multiple components in the formula form a closed-loop cooperative multi-target intervention retina microenvironment, the problems of component dispersion and the like are solved through the combined process, and biocompatibility and compliance are both considered.

The utility model belongs to the technical field of anesthesia devices, and particularly relates to an anesthesiology concentration adjusting type anesthesia device which comprises a bottom plate, a supporting column, a top plate, an anesthetic storage tank, a diluent storage tank, a first liquid outlet pipe, a second liquid outlet pipe, a liquid pushing mechanism, a mixing tank, a support, a stirring mechanism, a valve, a liquid discharging pipe and a controller. When in use, the controller is used for controlling the opening and closing of the flow control valves arranged at the liquid inlets of the two liquid pushing mechanisms, and the flow control valves are used for quantitatively regulating and controlling the added anesthetic and diluent, so that the automatic blending of liquid medicine mixing is realized, the burden of medical personnel is reduced, and after adding is completed, the anesthetic and diluent can be automatically mixed. The inner rod in the telescopic rod pushes the piston to be pushed towards the push-out opening in the cavity of the cylinder body, so that liquid left on the inner wall of the cylinder body is pushed into the mixing tank from the push-out opening, the situation that due to residual medicine, the concentration of matched medicine generates an error is avoided, and accurate concentration adjustment is achieved.